glycine has been researched along with Cystic Fibrosis of Pancreas in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of taurine supplementation (30 to 40 mg/kg/24 hr) on fat absorption and related measurements was examined in 21 preadolescent children with cystic fibrosis (CF) using a 12-month double-blind crossover technique." | 9.06 | Taurine supplementation, fat absorption, and growth in cystic fibrosis. ( Davidson, GP; Robb, TA; Thompson, GN, 1987) |
| "Bile acid taurine deficiency is common in cystic fibrosis (CF) and is thought to be associated with impaired fat absorption." | 7.67 | Assessment of taurine deficiency in cystic fibrosis. ( Thompson, GN, 1988) |
| "The effect of taurine supplementation (30 to 40 mg/kg/24 hr) on fat absorption and related measurements was examined in 21 preadolescent children with cystic fibrosis (CF) using a 12-month double-blind crossover technique." | 5.06 | Taurine supplementation, fat absorption, and growth in cystic fibrosis. ( Davidson, GP; Robb, TA; Thompson, GN, 1987) |
| "VX-770 (Ivacaftor) has been approved for clinical usage in cystic fibrosis patients with several CFTR mutations." | 3.83 | Potentiators exert distinct effects on human, murine, and Xenopus CFTR. ( Cui, G; Imhoff, BR; Infield, DT; Khazanov, N; McCarty, NA; Senderowitz, H; Stauffer, BB, 2016) |
| " The mutation, a cysteine for glycine substitution at residue 480 (G480C), was detected in a pancreatic insufficient, African-American, cystic fibrosis (CF) patient." | 3.69 | Missense mutation (G480C) in the CFTR gene associated with protein mislocalization but normal chloride channel activity. ( Cohn, JA; Cole, JL; Cutting, GR; Dawson, DC; Macek, M; Mansoura, MK; Smit, LS; Strong, TV; Wilkinson, DJ; Wood, DL, 1995) |
| "The glycine-to-aspartic acid missense mutation at codon 551 (G551D), which is within the first nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator (CFTR), is the third most common cystic fibrosis (CF) mutation, with a worldwide frequency of 3." | 3.68 | Cystic fibrosis patients bearing both the common missense mutation Gly----Asp at codon 551 and the delta F508 mutation are clinically indistinguishable from delta F508 homozygotes, except for decreased risk of meconium ileus. ( Brock, DJ; Corey, M; Durie, P; Hamosh, A; Keston, M; King, TM; Levison, H; McIntosh, I; Rosenstein, BJ; Tsui, LC, 1992) |
| "To evaluate the relative efficacy of nonelemental versus semielemental enteral supplements for nutritional rehabilitation of cystic fibrosis (CF) patients, whole-body protein turnover using the [15N]glycine method was studied in nine malnourished CF patients during enteral feedings, in a block design study comparing a semielemental formula (Criticare), a higher protein density but nonelemental formula (Traumacal) (T), and a nonelemental formula that had been modified to become isocaloric and isonitrogenous to the semielemental formula (modified Traumacal, MT)." | 3.68 | Protein turnover in malnourished patients with cystic fibrosis: effects of elemental and nonelemental nutritional supplements. ( Cleghorn, GJ; Holt, TL; Pelekanos, JT; Shepherd, RW; Ward, LC, 1990) |
| "Bile acid taurine deficiency is common in cystic fibrosis (CF) and is thought to be associated with impaired fat absorption." | 3.67 | Assessment of taurine deficiency in cystic fibrosis. ( Thompson, GN, 1988) |
| "CF (cystic fibrosis) is caused by mutations in CFTR (CF transmembrane conductance regulator), which cause its mistrafficking and/or dysfunction as a regulated chloride channel on the apical surface of epithelia." | 1.35 | Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease. ( Bear, CE; Li, C; Pasyk, S; Ramjeesingh, M, 2009) |
| "Bile is lithogenic in untreated cystic fibrosis and responds to pancreatic enzymes." | 1.26 | Abnormal biliary lipid composition in cystic fibrosis. Effect of pancreatic enzymes. ( Combes, JC; Lasalle, R; Mégevand, A; Morin, CL; Nusslé, D; Roy, CC; Weber, AM, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (20.59) | 18.7374 |
| 1990's | 8 (23.53) | 18.2507 |
| 2000's | 8 (23.53) | 29.6817 |
| 2010's | 9 (26.47) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Tabori, H | 1 |
| Schneider, J | 1 |
| Lüth, S | 1 |
| Zagoya, C | 1 |
| Barucha, A | 1 |
| Lehmann, T | 1 |
| Kauf, E | 1 |
| Barth, A | 1 |
| Mainz, JG | 1 |
| Zagefka, H | 1 |
| Huynh, HP | 1 |
| Senger, AR | 1 |
| Derington, CG | 1 |
| Colantonio, LD | 1 |
| Herrick, JS | 1 |
| Cook, J | 1 |
| King, JB | 1 |
| Rosenson, RS | 1 |
| Poudel, B | 1 |
| Monda, KL | 1 |
| Navar, AM | 1 |
| Mues, KE | 1 |
| Stevens, VW | 1 |
| Nelson, RE | 1 |
| Vanneman, ME | 1 |
| Muntner, P | 1 |
| Bress, AP | 1 |
| Ma, B | 1 |
| Ren, G | 1 |
| Xu, J | 1 |
| Yin, C | 1 |
| Shi, Y | 1 |
| Rahsepar, AA | 1 |
| Bluemke, DA | 1 |
| Habibi, M | 1 |
| Liu, K | 1 |
| Kawel-Boehm, N | 1 |
| Ambale-Venkatesh, B | 1 |
| Fernandes, VRS | 1 |
| Rosen, BD | 1 |
| Lima, JAC | 1 |
| Carr, JC | 1 |
| Freitag, TM | 1 |
| Chen-Sankey, JC | 1 |
| Duarte, DA | 1 |
| Ramsey, MW | 1 |
| Choi, K | 1 |
| Winkler-Heil, R | 1 |
| Hussain, M | 1 |
| Hofmann, W | 1 |
| Nicotera, AG | 1 |
| Dicanio, D | 1 |
| Pironti, E | 1 |
| Bonsignore, M | 1 |
| Cafeo, A | 1 |
| Efthymiou, S | 1 |
| Mondello, P | 1 |
| Salpietro, V | 1 |
| Houlden, H | 1 |
| Di Rosa, G | 1 |
| Hayes-Ryan, D | 1 |
| O'Donoghue, K | 1 |
| McCarthy, C | 1 |
| Totorika, A | 1 |
| Meaney, S | 1 |
| Pang, RD | 1 |
| Dormanesh, A | 1 |
| Hoang, Y | 1 |
| Chu, M | 1 |
| Allem, JP | 1 |
| Girón-Ortega, JA | 1 |
| Márquez-Coello, M | 1 |
| Gutiérrez-Saborido, D | 1 |
| Arizcorreta, A | 1 |
| Cuesta-Sancho, S | 1 |
| Girón-González, JA | 1 |
| Dovrat, G | 1 |
| Pevzner, S | 1 |
| Berthon, C | 1 |
| Lerner, A | 1 |
| Maimon, E | 1 |
| Vainer, R | 1 |
| Karpasas, M | 1 |
| Ben-Elyiahu, Y | 1 |
| Moisy, P | 1 |
| Bettelheim, A | 1 |
| Zilbermann, I | 1 |
| Vanden Broeck, SMP | 1 |
| Nelson, DJ | 1 |
| Collado, A | 1 |
| Falivene, L | 1 |
| Cavallo, L | 1 |
| Cordes, DB | 1 |
| Slawin, AMZ | 1 |
| Van Hecke, K | 1 |
| Nahra, F | 1 |
| Cazin, CSJ | 1 |
| Nolan, SP | 1 |
| Kranidiotis-Hisatomi, N | 1 |
| Yi, H | 1 |
| Oestreich, M | 1 |
| Kwiezinski, C | 1 |
| Weller, C | 1 |
| van Pinxteren, D | 1 |
| Brüggemann, M | 1 |
| Mertes, S | 1 |
| Stratmann, F | 1 |
| Herrmann, H | 1 |
| Treggiari, D | 1 |
| Tridello, G | 1 |
| Menin, L | 1 |
| Borruso, A | 1 |
| Pintani, E | 1 |
| Iansa, P | 1 |
| Cipolli, M | 1 |
| Melotti, P | 1 |
| Ren, L | 1 |
| Liu, L | 3 |
| Shu, X | 1 |
| Lin, W | 1 |
| Yang, P | 1 |
| Chen, J | 1 |
| Teo, KL | 1 |
| Xiao, F | 1 |
| Wang, H | 1 |
| Yao, T | 1 |
| Zhao, X | 1 |
| Yang, X | 1 |
| Yu, DYW | 1 |
| Rogach, AL | 1 |
| Bordet, A | 1 |
| Leitner, W | 1 |
| Gao, S | 1 |
| Xia, F | 1 |
| Li, B | 2 |
| Abdul Razak, IB | 1 |
| Liu, Y | 1 |
| Lu, K | 1 |
| Brown, DE | 1 |
| Wang, R | 1 |
| Cheng, Y | 1 |
| Ni, S | 1 |
| Qu, H | 1 |
| Xing, H | 1 |
| Xu, Z | 1 |
| Zhu, X | 1 |
| Yuan, M | 1 |
| Wang, L | 1 |
| Yu, J | 1 |
| Li, Y | 1 |
| Yang, L | 1 |
| Liu, H | 1 |
| Cao, L | 1 |
| Zhang, S | 1 |
| Zhao, D | 1 |
| Yan, T | 1 |
| Yang, G | 1 |
| Lin, Z | 1 |
| Luo, M | 1 |
| Ye, N | 1 |
| Lee, SW | 1 |
| Carnicelli, J | 1 |
| Getya, D | 1 |
| Gitsov, I | 1 |
| Phillips, KS | 1 |
| Ren, D | 1 |
| Grützmacher, PG | 1 |
| Suarez, S | 1 |
| Tolosa, A | 1 |
| Gachot, C | 1 |
| Song, G | 1 |
| Wang, B | 1 |
| Presser, V | 1 |
| Mücklich, F | 1 |
| Anasori, B | 1 |
| Rosenkranz, A | 1 |
| Demireva, M | 1 |
| Armentrout, PB | 1 |
| Feng, D | 1 |
| Cao, K | 1 |
| He, ZZ | 1 |
| Knibbs, LD | 1 |
| Jalaludin, B | 1 |
| Leskinen, A | 1 |
| Roponen, M | 1 |
| Komppula, M | 1 |
| Jalava, P | 1 |
| Guo, PY | 1 |
| Xu, SL | 1 |
| Yang, BY | 1 |
| Hu, L | 1 |
| Zeng, XW | 1 |
| Chen, G | 1 |
| Yu, HY | 1 |
| Lin, L | 1 |
| Dong, G | 1 |
| Machulkin, AE | 1 |
| Shafikov, RR | 1 |
| Uspenskaya, AA | 1 |
| Petrov, SA | 1 |
| Ber, AP | 1 |
| Skvortsov, DA | 1 |
| Nimenko, EA | 1 |
| Zyk, NU | 1 |
| Smirnova, GB | 1 |
| Pokrovsky, VS | 1 |
| Abakumov, MA | 1 |
| Saltykova, IV | 1 |
| Akhmirov, RT | 1 |
| Garanina, AS | 1 |
| Polshakov, VI | 1 |
| Saveliev, OY | 1 |
| Ivanenkov, YA | 1 |
| Aladinskaya, AV | 1 |
| Finko, AV | 1 |
| Yamansarov, EU | 1 |
| Krasnovskaya, OO | 1 |
| Erofeev, AS | 1 |
| Gorelkin, PV | 1 |
| Dontsova, OA | 1 |
| Beloglazkina, EK | 1 |
| Zyk, NV | 1 |
| Khazanova, ES | 1 |
| Majouga, AG | 1 |
| Zheng, YK | 1 |
| Su, BJ | 1 |
| Wang, YQ | 1 |
| Wang, HS | 1 |
| Liao, HB | 1 |
| Liang, D | 1 |
| Shataer, D | 1 |
| Li, J | 1 |
| Duan, XM | 1 |
| Xin, XL | 1 |
| Aisa, HA | 1 |
| Allu, SR | 1 |
| Ravotto, L | 1 |
| Troxler, T | 1 |
| Vinogradov, SA | 1 |
| Cheruku, RR | 1 |
| Tracy, EC | 1 |
| Tabaczynski, W | 1 |
| Missert, JR | 1 |
| Baumann, H | 1 |
| Pandey, RK | 1 |
| Rohde, JM | 1 |
| Karavadhi, S | 1 |
| Pragani, R | 1 |
| Fang, Y | 1 |
| Zhang, W | 1 |
| McIver, A | 1 |
| Zheng, H | 1 |
| Liu, Q | 1 |
| Davis, MI | 1 |
| Urban, DJ | 1 |
| Lee, TD | 1 |
| Cheff, DM | 1 |
| Hollingshead, M | 1 |
| Henderson, MJ | 1 |
| Martinez, NJ | 1 |
| Brimacombe, KR | 1 |
| Yasgar, A | 1 |
| Zhao, W | 1 |
| Klumpp-Thomas, C | 1 |
| Michael, S | 1 |
| Covey, J | 1 |
| Moore, WJ | 1 |
| Stott, GM | 1 |
| Li, Z | 1 |
| Simeonov, A | 1 |
| Jadhav, A | 1 |
| Frye, S | 1 |
| Hall, MD | 1 |
| Shen, M | 1 |
| Wang, X | 1 |
| Patnaik, S | 1 |
| Boxer, MB | 1 |
| Zhang, H | 2 |
| Cheng, C | 1 |
| Huang, B | 1 |
| Chen, R | 1 |
| Huang, Y | 1 |
| Chen, H | 1 |
| Pei, W | 1 |
| Katahara, S | 1 |
| Sugiyama, Y | 1 |
| Yamane, M | 1 |
| Komiya, Y | 1 |
| Sato, T | 1 |
| Chida, N | 1 |
| Vargas, MH | 1 |
| Del-Razo-Rodríguez, R | 1 |
| López-García, A | 1 |
| Lezana-Fernández, JL | 1 |
| Chávez, J | 1 |
| Furuya, MEY | 1 |
| Marín-Santana, JC | 1 |
| Adam, D | 1 |
| Bilodeau, C | 1 |
| Sognigbé, L | 1 |
| Maillé, É | 1 |
| Ruffin, M | 1 |
| Brochiero, E | 1 |
| Edlund, A | 1 |
| Esguerra, JL | 1 |
| Wendt, A | 1 |
| Flodström-Tullberg, M | 1 |
| Eliasson, L | 1 |
| Cui, G | 1 |
| Khazanov, N | 1 |
| Stauffer, BB | 1 |
| Infield, DT | 1 |
| Imhoff, BR | 1 |
| Senderowitz, H | 1 |
| McCarty, NA | 1 |
| Pasyk, S | 1 |
| Li, C | 1 |
| Ramjeesingh, M | 1 |
| Bear, CE | 1 |
| Hagins, JM | 1 |
| Locy, R | 1 |
| Silo-Suh, L | 1 |
| Masvidal, L | 1 |
| Giménez, J | 1 |
| Ramos, MD | 1 |
| Domingo, C | 1 |
| Farré, A | 1 |
| Bassas, L | 1 |
| Casals, T | 1 |
| Mills, AD | 1 |
| Yoo, C | 1 |
| Butler, JD | 1 |
| Yang, B | 1 |
| Verkman, AS | 3 |
| Kurth, MJ | 1 |
| Dubarry, N | 1 |
| Du, W | 1 |
| Lane, D | 1 |
| Pasta, F | 1 |
| Patrick, AE | 1 |
| Karamyshev, AL | 1 |
| Millen, L | 1 |
| Thomas, PJ | 1 |
| Gontijo-Amaral, C | 1 |
| Guimarães, EV | 1 |
| Camargos, P | 1 |
| Synder, D | 1 |
| Tradtrantip, L | 1 |
| Thiagarajah, JR | 1 |
| Anderson, MO | 1 |
| KAESER, H | 1 |
| COTTIER, P | 1 |
| ANTENER, I | 1 |
| Melin, P | 1 |
| Thoreau, V | 1 |
| Norez, C | 1 |
| Bilan, F | 1 |
| Kitzis, A | 1 |
| Becq, F | 1 |
| Decaestecker, K | 1 |
| Decaestecker, E | 1 |
| Castellani, C | 1 |
| Jaspers, M | 1 |
| Cuppens, H | 1 |
| De Boeck, K | 1 |
| Lukacs, GL | 1 |
| Galietta, LJ | 1 |
| Smit, LS | 1 |
| Strong, TV | 1 |
| Wilkinson, DJ | 1 |
| Macek, M | 1 |
| Mansoura, MK | 1 |
| Wood, DL | 1 |
| Cole, JL | 1 |
| Cutting, GR | 1 |
| Cohn, JA | 1 |
| Dawson, DC | 1 |
| Morrison, RT | 1 |
| Steuart, RD | 1 |
| Chaun, H | 1 |
| Fortunati, E | 1 |
| Bout, A | 1 |
| Zanta, MA | 1 |
| Valerio, D | 1 |
| Scarpa, M | 2 |
| Cartault, F | 1 |
| Steffann, J | 1 |
| Vidaud, D | 1 |
| Bousquet, S | 1 |
| Lesure, F | 1 |
| Renouil, M | 1 |
| McDonell, N | 1 |
| Feingold, J | 1 |
| Beldjord, C | 1 |
| Bienvenu, T | 1 |
| Picci, L | 1 |
| Cameran, M | 1 |
| Olante, P | 1 |
| Zacchello, F | 1 |
| Thomas, GR | 1 |
| Costelloe, EA | 1 |
| Lunn, DP | 1 |
| Stacey, KJ | 1 |
| Delaney, SJ | 1 |
| Passey, R | 1 |
| McGlinn, EC | 1 |
| McMorran, BJ | 1 |
| Ahadizadeh, A | 1 |
| Geczy, CL | 1 |
| Wainwright, BJ | 1 |
| Hume, DA | 1 |
| Foster, JA | 1 |
| Ramsden, WH | 1 |
| Conway, SP | 1 |
| Taylor, JM | 1 |
| Etherington, C | 1 |
| Lefebvre, D | 1 |
| Ratelle, S | 1 |
| Chartrand, L | 1 |
| Roy, CC | 2 |
| Weber, AM | 1 |
| Morin, CL | 1 |
| Combes, JC | 1 |
| Nusslé, D | 1 |
| Mégevand, A | 1 |
| Lasalle, R | 1 |
| Hamosh, A | 1 |
| King, TM | 1 |
| Rosenstein, BJ | 1 |
| Corey, M | 1 |
| Levison, H | 1 |
| Durie, P | 1 |
| Tsui, LC | 1 |
| McIntosh, I | 1 |
| Keston, M | 1 |
| Brock, DJ | 1 |
| Franciolini, F | 1 |
| Petris, A | 1 |
| Pelekanos, JT | 1 |
| Holt, TL | 1 |
| Ward, LC | 1 |
| Cleghorn, GJ | 1 |
| Shepherd, RW | 1 |
| Thompson, GN | 3 |
| Robb, TA | 1 |
| Davidson, GP | 1 |
| Lane, JI | 1 |
| Sacks, D | 1 |
| Winn, RS | 1 |
| Kershner, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation[NCT04443673] | 59 participants (Actual) | Interventional | 2020-06-15 | Terminated (stopped due to An interim analysis showed no difference in major outcomes (n=35 glycine and n=24 control participants)) | |||
| Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481] | Phase 2 | 13 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to Some of the researchers finished their participation in the study.) | ||
| Characterization of β-cell Function and Insulin Sensitivity in Pre-transplant Patients With Cystic Fibrosis[NCT04379726] | 150 participants (Anticipated) | Observational | 2020-07-01 | Not yet recruiting | |||
| Phase II Study: LYM-X-SORB™, an Organized Lipid Matrix: Fatty Acids and Choline in CF[NCT00406536] | Phase 2 | 110 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.3908 |
| Placebo | 0.2035 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.0819 |
| Placebo | 0.1668 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.00007 |
| Placebo | 0.1739 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cough questionnaire score | Appetite questionnaire score | Energy questionnaire score | Body weight | Height | Heart rate | Respiratory rate | Temperature | |
| Glycine | 81.1 | 89.1 | 84.6 | 101.6 | 100.5 | 103.5 | 94.8 | 100.0 |
| Placebo | 89.1 | 132.1 | 111.5 | 103.6 | 100.5 | 98.1 | 109.0 | 100.1 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Forced expiratory volume at first second (FEV1) | Forced expiratory flow at 25%FVC (FEF25) | Maximal forced expiratory flow (FEFmax, PEFR) | |
| Glycine | 109.7 | 133.9 | 115.3 |
| Placebo | 91.4 | 83.3 | 91.2 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |
|---|---|---|
| Forced vital capacity (FVC) | Forced expiratory flow at 75%FVC (FEF75) | |
| Glycine | 104.1 | 111.8 |
| Placebo | 100.6 | 108.9 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Peripheral oxygen saturation (SpO2) | FEV1/FVC | Forced expiratory flow at 50%FVC (FEF50) | |
| Glycine | 105.2 | 105.2 | 115.5 |
| Placebo | 98.9 | 94.9 | 93.1 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Sputum questionnaire score | Dyspnea questionnaire score | Total questionnaire score | |
| Glycine | 82.0 | 75.6 | 77.7 |
| Placebo | 102.6 | 103.8 | 98.7 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-4 | IL-6 | IL-7 | IL-8 | IL-12 | IL-13 | G-CSF | IFN-gamma | MCP-1 | MIP-1beta | |
| Glycine | -0.4361 | -0.1635 | 0.2964 | 0.0085 | 0.0356 | -0.1466 | 0.3203 | -0.0561 | -0.0776 | 0.3272 | -0.0836 | 0.0330 |
| Placebo | -0.2906 | -0.0352 | 0.1470 | 0.2255 | 0.0819 | -0.2364 | 0.2603 | 0.1953 | 0.2272 | 0.3639 | 0.0472 | -0.0608 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-2 | IL-4 | IL-5 | IL-7 | IL-8 | IL-10 | IL-12 | IL-13 | IL-17 | IFN-gamma | MCP-1 | MIP-1beta | TNF-alpha | GM-CSF | |
| Glycine | 0.1294 | -0.0918 | 0.0233 | -0.0161 | 0.2498 | 0.0611 | -0.0824 | 0.0549 | 0.1675 | 0.1630 | 0.0680 | 0.0248 | 0.0042 | -0.0303 | 0.0412 | -0.0538 |
| Placebo | 0.0669 | -0.0102 | -0.0274 | 0.0522 | 0.1304 | 0.1387 | 0.0542 | 0.0074 | 0.0677 | 0.0953 | 0.1140 | 0.0649 | 0.2608 | 0.0977 | 0.1568 | -0.0822 |
3 reviews available for glycine and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
CFTR inhibitors.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Discovery; Glyci | 2013 |
CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.
Topics: Animals; Antidiarrheals; Biosensing Techniques; Cell Line; Chlorides; Cystic Fibrosis; Cystic Fibros | 2006 |
Chloride channels of biological membranes.
Topics: Animals; Biological Transport; Calcium; Cell Membrane; Chloride Channels; Chlorides; Cystic Fibrosis | 1990 |
3 trials available for glycine and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial.
Topics: Administration, Oral; Adolescent; Anti-Inflammatory Agents; Biomarkers; Child; Cross-Over Studies; C | 2017 |
Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial.
Topics: Administration, Oral; Adolescent; Anti-Inflammatory Agents; Biomarkers; Child; Cross-Over Studies; C | 2017 |
Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial.
Topics: Administration, Oral; Adolescent; Anti-Inflammatory Agents; Biomarkers; Child; Cross-Over Studies; C | 2017 |
Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial.
Topics: Administration, Oral; Adolescent; Anti-Inflammatory Agents; Biomarkers; Child; Cross-Over Studies; C | 2017 |
Oral magnesium supplementation in children with cystic fibrosis improves clinical and functional variables: a double-blind, randomized, placebo-controlled crossover trial.
Topics: Adolescent; Adult; Child; Cross-Over Studies; Cystic Fibrosis; Dietary Supplements; Double-Blind Met | 2012 |
Taurine supplementation, fat absorption, and growth in cystic fibrosis.
Topics: Body Height; Body Weight; Child; Child, Preschool; Clinical Trials as Topic; Cystic Fibrosis; Dietar | 1987 |
28 other studies available for glycine and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with
Topics: Bile Acids and Salts; Cholic Acid; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regula | 2022 |
Topics: Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Animals; Anti-Bacterial Agents; Anti- | 2021 |
CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproducts.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cells, Cultured; Chloride Channel Agonists; Cystic Fibr | 2018 |
CFTR and Anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic beta-cells.
Topics: Animals; Anoctamin-1; Calcium; Calcium Channels; Chloride Channels; Colforsin; Cyclic AMP; Cystic Fi | 2014 |
Potentiators exert distinct effects on human, murine, and Xenopus CFTR.
Topics: Amino Acid Sequence; Aminophenols; Animals; Cells, Cultured; Chloride Channel Agonists; Cystic Fibro | 2016 |
Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Cell Line; Cresols; Cystic Fibrosis; Cys | 2009 |
Isocitrate lyase supplies precursors for hydrogen cyanide production in a cystic fibrosis isolate of Pseudomonas aeruginosa.
Topics: Adaptation, Physiological; Carrier State; Cystic Fibrosis; D-Amino-Acid Oxidase; Gene Expression Reg | 2009 |
The p.Arg258Gly mutation in intracellular loop 2 of CFTR is associated with CFTR-related disorders.
Topics: Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Arginine; Cohort Studies; Cystic Fibrosis | 2009 |
Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Design; Glycine; Humans; | 2010 |
Improved electrotransformation and decreased antibiotic resistance of the cystic fibrosis pathogen Burkholderia cenocepacia strain J2315.
Topics: Base Sequence; Burkholderia cepacia complex; Culture Media; Cystic Fibrosis; DNA Methylation; DNA Pr | 2010 |
Alteration of CFTR transmembrane span integration by disease-causing mutations.
Topics: Cell Membrane; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Ret | 2011 |
[Gluco-glycinuria, a new familial syndrome].
Topics: Body Fluids; Cystic Fibrosis; Glycine; Glycosuria; Humans; Kidney Diseases; Medical Records; Syndrom | 1961 |
The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein.
Topics: Amino Acid Motifs; Animals; Aspartic Acid; COS Cells; Cystic Fibrosis; Cystic Fibrosis Transmembrane | 2004 |
Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients.
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Chlorocebus aethiops; Cohort Studies; COS Cells | 2004 |
Missense mutation (G480C) in the CFTR gene associated with protein mislocalization but normal chloride channel activity.
Topics: Animals; Base Sequence; Cells, Cultured; Chloride Channels; Cyclic AMP; Cysteine; Cystic Fibrosis; F | 1995 |
Multifocal uptake of Tc-99m mebrofenin in dilated liver ductules in a patient with cystic fibrosis.
Topics: Adult; Aniline Compounds; Bile Ducts, Intrahepatic; Cholestasis, Intrahepatic; Cystic Fibrosis; Dila | 1995 |
In vitro and in vivo gene transfer to pulmonary cells mediated by cationic liposomes.
Topics: 3T3 Cells; Adenoviridae; Animals; beta-Galactosidase; Bronchi; Cations; Cell Line; Cells, Cultured; | 1996 |
Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G, S1255L) and one novel polymorphism (L49L)
Topics: Alanine; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; France; Glycine; Huma | 1998 |
Identification of a D579G homozygote cystic fibrosis patient with pancreatic sufficiency and minor lung involvement. Mutations in brief no. 221. Online.
Topics: Adult; Amino Acid Substitution; Aspartic Acid; Cystic Fibrosis; Exocrine Pancreatic Insufficiency; F | 1999 |
G551D cystic fibrosis mice exhibit abnormal regulation of inflammation in lungs and macrophages.
Topics: Amino Acid Substitution; Animals; Aspartic Acid; Biomarkers; Bone Marrow Cells; Cell Movement; Cysti | 2000 |
The role of IDA scintigraphy in the follow-up of liver disease in patients with cystic fibrosis.
Topics: Adolescent; Adult; Aniline Compounds; Child; Cystic Fibrosis; Female; Follow-Up Studies; Glycine; Hu | 2002 |
Reduced microbial transformation of bile acids in cystic fibrosis.
Topics: Adolescent; Bile Acids and Salts; Chenodeoxycholic Acid; Child; Child, Preschool; Cholic Acids; Cyst | 1977 |
Abnormal biliary lipid composition in cystic fibrosis. Effect of pancreatic enzymes.
Topics: Bile; Bile Acids and Salts; Child; Cholelithiasis; Cholesterol; Cholic Acids; Cystic Fibrosis; Femal | 1977 |
Cystic fibrosis patients bearing both the common missense mutation Gly----Asp at codon 551 and the delta F508 mutation are clinically indistinguishable from delta F508 homozygotes, except for decreased risk of meconium ileus.
Topics: Adolescent; Aspartic Acid; Child; Child, Preschool; Codon; Cystic Fibrosis; Cystic Fibrosis Transmem | 1992 |
Protein turnover in malnourished patients with cystic fibrosis: effects of elemental and nonelemental nutritional supplements.
Topics: Adolescent; Child; Child Nutrition Disorders; Child Nutritional Physiological Phenomena; Child, Pres | 1990 |
Failure of taurine to improve fat absorption in cystic fibrosis.
Topics: Adolescent; Child; Cystic Fibrosis; Female; Glycine; Humans; Intestinal Absorption; Lipid Metabolism | 1988 |
Assessment of taurine deficiency in cystic fibrosis.
Topics: Adolescent; Bile; Child; Child, Preschool; Cystic Fibrosis; Female; Glycine; Humans; Leukocytes; Liv | 1988 |
A false-positive hepatobiliary scan in a patient with cystic fibrosis.
Topics: Adult; Aniline Compounds; Biliary Tract; Cholecystitis; Cystic Fibrosis; False Positive Reactions; F | 1988 |